Valuation: Hyundai Bioscience Co., Ltd.

Capitalization 1,015B 678M 583M 534M 504M 932M 65.5B 947M 6.33B 2.48B 30.92B 2.54B 2.49B 108B P/E ratio 2024
-81.1x
P/E ratio 2025 -21.1x
Enterprise value 993B 663M 570M 522M 493M 912M 64.06B 926M 6.19B 2.42B 30.24B 2.49B 2.44B 105B EV / Sales 2024
38.9x
EV / Sales 2025 129x
Free-Float
89.81%
Yield 2024 *
-
Yield 2025 -
Mar. 18 Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Jan. 14 Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus CI
Nov. 14 Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-10-01 Hyundai Bioscience Co., Ltd. announced that it has received KRW 15 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd. CI
25-09-23 Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd. CI
25-08-14 Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-17 Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-14 Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-09-17 Hyundai Bioscience USA Signs an MOU with the University of California San Diego to Conduct an Investigator-Initiated Trial to Evaluate the Efficacy of Xafty CI
24-08-28 Hyundai Bioscience Co., Ltd. to Conduct Phase 3 Clinical Trial for High-Risk Group of COVID-19 Patients with the Goal of Emergency Use Authorization CI
24-08-14 Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-06-18 Hyundai Bioscience Co., Ltd. announced that it has received KRW 3 billion in funding CI
1 day-4.28%
1 week-13.70%
Current month-21.49%
1 month-29.44%
3 months-23.04%
6 months+116.68%
Current year+111.88%
1 week 10,000
Extreme 10000
12,610
1 month 10,000
Extreme 10000
16,060
Current year 4,645
Extreme 4645
21,500
1 year 4,325
Extreme 4325
21,500
3 years 4,325
Extreme 4325
21,500
5 years 4,325
Extreme 4325
21,500
10 years 1,835
Extreme 1835
33,150
Manager TitleAgeSince
Chief Executive Officer 66 2013-03-28
Corporate Officer/Principal 46 -
Corporate Officer/Principal 62 -
Director TitleAgeSince
Director/Board Member 66 2013-03-28
Director/Board Member 68 -
Director/Board Member 46 -
Change 5d. change 1-year change 3-years change Capi.($)
-4.28%-13.70%+95.72%-8.52% 678M
+0.81%+0.14%-14.01%-7.01% 332B
-0.21%+1.13%-19.29%-10.86% 125B
+0.37%+2.82%-1.78%+13.04% 72.3B
+0.03%-1.66%-6.45%-16.17% 59.12B
+0.99%+0.76%-28.22%-36.39% 33.25B
+2.71%-4.79%+18.34%-60.88% 28.29B
-0.31%+2.71%-10.20%-18.38% 18.5B
+2.01%+3.03%-40.74%-43.49% 18.3B
+0.08%+0.54%-6.12%+12.15% 16.86B
Average +0.15%-0.86%-1.27%-17.65% 70.44B
Weighted average by Cap. +0.21%+0.36%-12.73%-10.74%

Financials

2024 2025
Net sales 15.05B 10.05M 8.65M 7.91M 7.48M 13.82M 971M 14.04M 93.82M 36.71M 458M 37.73M 36.93M 1.6B 3.52B 2.35M 2.02M 1.85M 1.75M 3.23M 227M 3.28M 21.93M 8.58M 107M 8.82M 8.63M 373M
Net income -6.93B -4.63M -3.98M -3.64M -3.44M -6.36M -447M -6.46M -43.2M -16.9M -211M -17.37M -17M -735M -22.13B -14.78M -12.71M -11.64M -10.99M -20.32M -1.43B -20.64M -138M -53.98M -674M -55.47M -54.3M -2.35B
Net Debt 22.94B 15.32M 13.18M 12.06M 11.4M 21.06M 1.48B 21.4M 143M 55.95M 699M 57.5M 56.28M 2.43B -22.29B -14.89M -12.81M -11.72M -11.08M -20.47M -1.44B -20.79M -139M -54.38M -679M -55.88M -54.7M -2.36B
Logo Hyundai Bioscience Co., Ltd.
HYUNDAI BIOSCIENCE CO., LTD. it is a Korea-based company mainly engaged in the manufacturing and sale of bio cosmetics and hair tonic products. It develops functional daily necessities such as shampoos, mask packs, creams, and tumor-targeted drug. The Company also sells liquid crystal display (LCD) monitors and digital signage display products. The Company distributes its products in domestic market, as well as to the overseas markets, including Europe, America and Japan.
Employees
69
Date Price Change Volume
26-05-20 10,520.00 -4.28% 3,743,801
26-05-19 10,990.00 +0.09% 2,786,899
26-05-18 10,980.00 -1.70% 1,365,353
26-05-15 11,170.00 -8.07% 2,528,193
26-05-14 12,150.00 -0.33% 1,383,991
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
  1. Stock Market
  2. Equities
  3. A048410 Stock